Int Ophthalmol. 2025 Jul 22;45(1):307. doi: 10.1007/s10792-025-03648-6.
ABSTRACT
BACKGROUND: Dry eye disease (DED) is a common inflammatory disease of the eye surface that significantly affects quality of life. The present study investigated the effect of a propylene glycol-hydroxypropyl guar (PG-HPG) nanoemulsion on objective non-invasive ocular surface status markers in individuals with mild to moderate dry eye disease.
METHODS: A nonrandomized clinical trial in fifty eyes from 25 healthy subjects with mild to moderate DED who applied one drop of PG-HPG nanoemulsion to each eye twice a day for three months. The primary outcomes measured changes in tear film osmolarity and meibography scores from baseline to three months.
RESULTS: There were statistically significant changes in meibography scores (p < 0.0001) and osmolarity (p = 0.0066) from baseline to three months. The average osmolarity decreased by approximately 6.17 units from baseline to three months. No statistically significant changes were observed in NIAVG, Schirmer’s test, or NIBUT from baseline to three months.
CONCLUSIONS: PG-HPG Nano-emulsion produced changes in objective non-invasive ocular surface status markers, including a reduction in meibography scores and tear film osmolarity at three months, further clinical studies on the effectiveness of PG-HPG against a comparator are to expand the evidence of its effectiveness as a therapeutic option and its effects on patient quality of life in DED management.
PMID:40694228 | DOI:10.1007/s10792-025-03648-6
